Otsuka Pharmaceutical Europe Ltd.

The European Commission Approves Samsca(TM) (tolvaptan), Europe’s First and Only Oral Vasopressin Antagonist for Hyponatraemia Secondary to Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)

TOKYO, Japan and UXBRIDGE, England - Otsuka Pharmaceutical Co., Ltd.